Kimme L Hyrich

24.7k total citations · 5 hit papers
313 papers, 12.2k citations indexed

About

Kimme L Hyrich is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Kimme L Hyrich has authored 313 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 216 papers in Rheumatology, 122 papers in Hematology and 66 papers in Immunology. Recurrent topics in Kimme L Hyrich's work include Rheumatoid Arthritis Research and Therapies (207 papers), Autoimmune and Inflammatory Disorders Research (119 papers) and Systemic Lupus Erythematosus Research (67 papers). Kimme L Hyrich is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (207 papers), Autoimmune and Inflammatory Disorders Research (119 papers) and Systemic Lupus Erythematosus Research (67 papers). Kimme L Hyrich collaborates with scholars based in United Kingdom, United States and Ireland. Kimme L Hyrich's co-authors include Deborah Symmons, Mark Lunt, Kath Watson, William G Dixon, Alan J. Silman, James Galloway, Louise Mercer, Suzanne Verstappen, Anne Barton and Andrew Ustianowski and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Kimme L Hyrich

298 papers receiving 11.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

2006 534 citations William G Dixon, K. Watson et al. profile →
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

2009 532 citations William G Dixon, Kimme L Hyrich et al. Annals of the Rheumatic Diseases profile →
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

2010 496 citations James Galloway, Kimme L Hyrich et al. Lara D. Veeken profile →
Juvenile idiopathic arthritis

2022 142 citations Kimme L Hyrich et al. profile →
Therapeutic advances in rheumatoid arthritis

2024 130 citations Philip M. Brown, Arthur G. Pratt et al. BMJ profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimme L Hyrich United Kingdom	63	7.6k	3.8k	3.2k	1.6k	1.3k	313	12.2k
A. Zink Germany	51	7.7k 1.0×	3.3k 0.9×	3.1k 1.0×	808 0.5×	903 0.7×	238	11.3k
Joachim Listing Germany	65	12.5k 1.6×	4.7k 1.2×	6.2k 1.9×	640 0.4×	804 0.6×	179	14.8k
Bernard Combe France	64	10.1k 1.3×	3.7k 1.0×	3.3k 1.0×	2.0k 1.2×	1.8k 1.4×	481	14.3k
Carlomaurizio Montecucco Italy	54	5.1k 0.7×	1.9k 0.5×	2.3k 0.7×	1.0k 0.6×	1.4k 1.1×	436	9.9k
Roberto Caporali Italy	56	5.7k 0.8×	1.7k 0.4×	2.2k 0.7×	1.1k 0.7×	1.1k 0.9×	450	10.4k
Ben A. C. Dijkmans Netherlands	83	18.3k 2.4×	6.1k 1.6×	6.3k 2.0×	2.1k 1.3×	2.3k 1.8×	332	25.0k
Michael T. Nurmohamed Netherlands	58	8.2k 1.1×	2.2k 0.6×	3.7k 1.2×	981 0.6×	863 0.7×	423	13.6k
M. A. van Leeuwen Netherlands	31	7.7k 1.0×	3.0k 0.8×	1.7k 0.5×	950 0.6×	1.3k 1.0×	39	10.0k
E. William St. Clair United States	55	9.1k 1.2×	3.2k 0.8×	5.3k 1.7×	2.3k 1.5×	1.7k 1.3×	170	16.5k
Maxime Dougados France	74	19.5k 2.6×	6.9k 1.8×	9.4k 2.9×	1.5k 0.9×	1.9k 1.4×	546	23.9k

Countries citing papers authored by Kimme L Hyrich

Since Specialization

Citations

This map shows the geographic impact of Kimme L Hyrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimme L Hyrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimme L Hyrich more than expected).

Fields of papers citing papers by Kimme L Hyrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimme L Hyrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimme L Hyrich. The network helps show where Kimme L Hyrich may publish in the future.

Co-authorship network of co-authors of Kimme L Hyrich

This figure shows the co-authorship network connecting the top 25 collaborators of Kimme L Hyrich. A scholar is included among the top collaborators of Kimme L Hyrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimme L Hyrich. Kimme L Hyrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kearsley‐Fleet, Lianne, et al.. (2024). Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK. Lara D. Veeken. 64(3). 1453–1458. 1 indexed citations

Tsoi, Man Fung, et al.. (2024). Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA. Lara D. Veeken. 64(2). 477–483. 1 indexed citations

Smith, Samantha, Saskia Lawson‐Tovey, Andrew D. Dick, et al.. (2024). Integration of Genetic and Clinical Risk Factors for Risk Classification of Uveitis in Patients With Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. 76(12). 1789–1796. 1 indexed citations

Brown, Philip M., Arthur G. Pratt, & Kimme L Hyrich. (2024). Therapeutic advances in rheumatoid arthritis. BMJ. 384. e070856–e070856. 130 indexed citations breakdown →

Ling, Stephanie F, Kayode Ogungbenro, Adam S. Darwich, et al.. (2024). Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. Pharmaceutics. 16(6). 702–702.

Andev, Rajinder S, Lianne Kearsley‐Fleet, K. Watson, et al.. (2023). AB0411 ASSOCIATION BETWEEN ETHNICITY AND INITIAL RESPONSE TO TNF INHIBITORS IN PEOPLE WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA). Annals of the Rheumatic Diseases. 82. 1391–1392.

Bluett, James, Kimme L Hyrich, Brian Keevil, Patty Doran, & Anne Barton. (2023). P106 Feasibility Study of Methotrexate use Improvement in Rheumatoid Arthritis using Biomarker Feedback: The MIRA Trial. Lara D. Veeken. 62(Supplement_2). 1 indexed citations

Kearsley‐Fleet, Lianne, Kim Lauper, Kath Watson, et al.. (2023). OA01 No difference in risk of myocardial infarction among patients receiving either IL6 or TNF inhibitors for rheumatoid arthritis. Lara D. Veeken. 62(Supplement_2). 1 indexed citations

Zhao, Sizheng Steven, Lianne Kearsley‐Fleet, Kath Watson, et al.. (2023). P144 Socioeconomic deprivation is associated with reduced response and lower treatment persistence with anti-TNF therapies in people with rheumatoid arthritis. Lara D. Veeken. 62(Supplement_2). 1 indexed citations

10.

Zhao, Sizheng Steven, Kimme L Hyrich, Zenas Z N Yiu, Anne Barton, & John Bowes. (2023). POS1604 IL-13 INHIBITION USED FOR ATOPIC DISEASES IS ASSOCIATED WITH RISK OF PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 82. 1146–1147. 1 indexed citations

11.

Gwinnutt, James M., Sam Norton, Kimme L Hyrich, et al.. (2022). Influence of Social Support, Financial Status, and Lifestyle on the Disparity Between Inflammation and Disability in Rheumatoid Arthritis. Arthritis Care & Research. 75(5). 1026–1035. 9 indexed citations

12.

Kerschbaumer, Andreas, Alexandre Sepriano, Sytske Anne Bergstra, et al.. (2022). Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 82(1). 95–106. 90 indexed citations

13.

Matcham, Faith, Rebecca Davies, Matthew Hotopf, et al.. (2018). The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. Lara D. Veeken. 57(5). 835–843. 82 indexed citations

14.

Kearsley‐Fleet, Lianne, Rebecca Davies, Mark Lunt, T. R. E. Southwood, & Kimme L Hyrich. (2015). Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Lara D. Veeken. 55(5). 840–847. 25 indexed citations

15.

Mercer, Louise, Adèle C. Green, James Galloway, et al.. (2012). The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases. 71(6). 869–874. 95 indexed citations

16.

Verstappen, Suzanne, et al.. (2010). Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Lara D. Veeken. 49(8). 1570–1577. 70 indexed citations

17.

Saad, Amr, Darren M. Ashcroft, Kath Watson, et al.. (2009). Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Research & Therapy. 11(2). R52–R52. 166 indexed citations

18.

Dixon, William G, Kristin Watson, Mark Lunt, et al.. (2006). Rates of Myocardial Infarction (MI) and Cerebrovascular Accident (CVA) are reduced in patients with Rheumatoid Arthritis (RA) treated with anti-TNF therapy compared to those treated with traditional DMARDS: Results from the BSR biologics register. Lara D. Veeken. 45. 4 indexed citations

19.

Watson, Kath, William G Dixon, Kimme L Hyrich, et al.. (2006). Influence of anti-tnf therapy and previous malignancy on cancer incidence in patients with Rheumatoid Arthritis (RA): Results from the BSR biologics register (BSRBR). Lara D. Veeken. 45. 11 indexed citations

20.

Watson, Kath, et al.. (2005). Anti-TNF therapy and mortality in rheumatoid arthritis patients registered with the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Diseases. 64. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact